RU2223727C2 - Method for treating the cases of erosions and ulcers of the cornea persisting for a long time - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: method involves covering cornea defect with a medical preparation and treating with permanent magnetic field. Protein-free hemodialyzate from calf blood and/or protein-free hemoderivate from calf blood is used as the medical preparation at a dose of 1-2 drops into an eye under treatment during 6-14 days. The permanent magnetic field of 120-160 mTesla units is applied daily during 2-8 min 1 to 3 times a day. The total treatment course is selected 12-28 sessions long. Mixture of protein-free hemodialyzate from calf blood with 50% by volume of protein-free hemoderivate from calf blood and protein-free hemoderivate from calf blood additionally containing low molecular weight peptides and nucleic acids derivates. EFFECT: enhanced effectiveness of treatment. 3 cl

Description

 The invention relates to medicine, to ophthalmology, to methods of treating long-term non-healing erosion and corneal ulcers.

 A known method of treating herpetic keratitis with the manifestations, comprising coating the defect with a drug with subsequent exposure to a magnetic field (RF patent 2164106, A 61 F 9/00, 2000).

 However, the known method when using it does not completely eliminate the eviscuration of the affected eye, does not provide high healing of erosion and corneal ulcers, and also does not exclude the re-occurrence of a purulent process.

 An object of the invention is to remedy these shortcomings and create a method for treating long-term non-healing erosion and corneal ulcers, which allows using it to exclude the eviscuration of the affected eye, to ensure high healing of erosion and corneal ulcers, and also to prevent the recurrence of a purulent process.

 The problem is solved in that a method for the treatment of long-term non-healing erosion and corneal ulcers is proposed, comprising coating a corneal defect with a drug, followed by exposure to erosion and corneal ulcer with a constant magnetic field with an inductance of 120-160 mT, while deproteinized hemodialysate from calf blood and / or deproteinized hemoderivative from calf blood 1-2 drops of the drug into the treated eye for 6-14 days. In this case, a mixture of deproteinized hemodialysate from the blood of calves with 50 vol. Is used as a medicine. % deproteinized hemoderivative from calf blood. In this case, a deproteinized hemoderivative from calf blood is used as a medicine, additionally containing low molecular weight peptides and nucleic acid derivatives. In this case, the effect on erosion and corneal ulcer by a constant magnetic field is carried out daily for 2-8 minutes 1 to 3 times a day, with the number of sessions selected from 12 to 28 per treatment course.

 Experimental studies of the proposed method for the treatment of long-term non-healing erosion and corneal ulcers under clinical conditions showed that, using all the distinguishing features of the proposed technical solution, the treatment of patients excluded ejaculation of the affected eye, ensuring high healing of erosion and corneal ulcers, and also eliminated the re-occurrence of purulent process .

 The implementation of the proposed method for the treatment of long-term non-healing erosion and corneal ulcers is illustrated by the following clinical examples.

 Example 1. Patient N., 46 years old, was admitted to the Kaluga branch of the State Institution MTC "Eye Microsurgery" with a diagnosis of "Long-term non-healing erosion of the cornea of the right eye." Visual acuity of 0.32, on the cornea in the paracentral zone, respectively 11 hours, oval erosion of 2.5x4 mm with edematous epithelium at the edges.

 Immediately before the session of magnetotherapy, 2 drops of deproteinized hemodialysate from the blood of calves were dripped onto the defect of the affected eye and exposed to the corneal defect with a constant magnetic field with an inductance of 160 mT daily for 6 days, 8 minutes, 2 times a day. At the same time, 12 sessions of magnetotherapy were carried out.

 Erosion is epithelialized. At discharge, visual acuity of 0.63, after three months, visual acuity of 0.8.

 Example 2. Patient A., 67 years old, was admitted to the Kaluga branch of GU MNTK "Eye Microsurgery" with a diagnosis of "Keratitis of the left eye with ulceration." Visual acuity of 0.2, on the cornea, respectively 6 hours, gross infiltration up to 4 mm in diameter and with an epithelial defect in the center of 2x2.5 mm.

 Immediately before a magnetic therapy session, 1 drop of deproteinized hemoderivative from calves’s blood, additionally containing low molecular weight peptides and nucleic acid derivatives, was dripped onto a defect of the affected eye and exposed to a corneal defect with a constant magnetic field with an inductance of 120 mT daily for 14 days for 2 minutes 2 times day. At the same time, 28 sessions of magnetotherapy were carried out.

 In the course of treatment, the epithelium was epithelized, and the infiltration decreased. At discharge, visual acuity of 0.5. After three months, visual acuity of 0.63, on the cornea, respectively 6 hours, local persistent translucent opacification of 2 mm in diameter, which does not affect visual acuity.

 Example 3. Patient P., 58 years old, was admitted to the Kaluga branch of the State Institution MTC "Eye Microsurgery" with a diagnosis of "Purulent ulcer of the cornea of the left eye." Visual acuity is 0.1, the cornea is edematous, respectively 3 hours purulent corneal ulcer 2.5x2 mm with saped edges and purulent infiltration around up to 5 mm in diameter. Fekomen "Tyndall" in the moisture of the anterior chamber.

 Immediately before a magnetic therapy session, 1 drop of deproteinized hemodialysate from calf blood and 1 drop of deproteinized hemoderivative from calf blood were dripped onto a defect of the affected eye immediately before a magnetic therapy session and the corneal defect was exposed to a constant magnetic field with an inductance of 140 mT daily for 7 days for 5 minutes 3 times a day. At the same time, 21 sessions of magnetotherapy were carried out.

 In the course of treatment, corneal edema passed, purulent infiltration around the ulcer decreased, the cornea was epitheliated. At discharge, visual acuity of 0.5. After three months, visual acuity of 0.63, on the cornea, respectively 3 hours, local persistent opacification, not affecting visual acuity.

 Example 4. Patient B., 69 years old, was admitted to the Kaluga branch of the State Institution MTC "Eye Microsurgery" with a diagnosis of "Neurotrophic keratitis of the left eye." Visual acuity of 0.5, on the periphery of the cornea, respectively 11 hours, a corneal ulcer in the form of a clouding of 1x3 mm, the edge of the ulcer is undermined.

 Immediately before the session of magnetotherapy, 2 drops of deproteinized hemodialysate from the blood of calves were dripped onto the defect of the affected eye and exposed to the corneal defect with a constant magnetic field with an inductance of 140 mT daily for 14 days for 8 minutes 1 time per day. At the same time, 14 sessions of magnetotherapy were carried out.

 The ulcer was epithelized, the infiltration resolved. Visual acuity at discharge 0.63, after three months, visual acuity 0.63.

Claims (3)

1. A method of treating long-term non-healing erosion and corneal ulcers, comprising coating a corneal defect with a drug, followed by exposure to a constant magnetic field, characterized in that deproteinized hemodialysate from calf blood and / or deproteinized hemoderivative from calf blood 1-2 are used as a medicine drops of the drug into the treated eye for 6-14 days, and the effect is carried out by a constant magnetic field with induction of 120-160 mT daily for 2-8 minutes 1-3 times a day, while TVO selected sessions 12-28 per course of treatment. 2. The method according to claim 1, characterized in that a mixture of deproteinized hemodialysate from calf blood with 50 vol.% Deproteinized hemoderivative from calf blood is used as a medicine. 3. The method according to any one of claims 1 or 2, characterized in that a deproteinized hemoderivative from calf blood is used as a medicine, further comprising low molecular weight peptides and nucleic acid derivatives.